SCHEMBL18072434

SCHEMBL18072434

CC(C)(C)OC(=O)NCc1cc(N)nc(C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CACNA1H O95180 1/20 0.45
▸ CACNA1B Q00975 1/20 0.45
▸ CACNA1C Q13936 1/20 0.45
▸ GRM2 Q14416 1/20 0.42
▸ KDM4A O75164 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ CA1 P00915 2/20 0.39
▸ CA2 P00918 2/20 0.39
▸ MAP3K5 Q99683 1/20 0.38
▸ NAMPT P43490 2/20 0.38
▸ TRPV1 Q8NER1 2/20 0.37
▸ DYRK1A Q13627 1/20 0.37
▸ CA12 O43570 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ HDAC1 Q13547 2/20 0.37
▸ GLS O94925 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ NSD2 O96028 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18072436 0.86 CACNA1H (0.44) CACNA1HCACNA1BCACNA1CGRM2KDM4A
SCHEMBL18072351 0.86 CACNA1H (0.46) CACNA1HCACNA1BCACNA1CGRM2KDM4A
SCHEMBL18072457 0.85 CACNA1H (0.43) CACNA1HCACNA1BCACNA1CGRM2KDM4A
SCHEMBL19755850 0.83 KDM4A (0.43) CACNA1HCACNA1BCACNA1CGRM2KDM4A
SCHEMBL18072358 0.82 CACNA1H (0.43) CACNA1HCACNA1BCACNA1CGRM2KDM4A
SCHEMBL18050066 0.81 TSHR (0.40) KDM4E
SCHEMBL18072471 0.80 CACNA1H (0.41) CACNA1HCACNA1BCACNA1CGRM2KDM4A
SCHEMBL19960739 0.79 LOXL2 (0.52) MAP3K5
SCHEMBL8247006 0.78 LOXL2 (0.47) CACNA1HCACNA1BCACNA1CGRM2KDM4A
SCHEMBL13055397 0.77 KDM4A (0.51) CACNA1HCACNA1BCACNA1CKDM4AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2021-07-27 — — US disclosed
CN-107592861-B Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof 法玛克亚公司 2021-06-08 — — CN disclosed
EP-3795568-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF Pharmakea, Inc. (US) 2021-03-24 — — EP disclosed
EP-3265456-B1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2020-11-18 — — EP disclosed
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2020-04-16 — — US disclosed
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof PHARMAKEA, INC. (US) 2020-02-25 — — US disclosed
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. 2019-04-25 — — US disclosed
CN-107592861-A It is fluorinated inhibitor of lysyloxidase sample 2 and application thereof 法玛克亚公司 2018-01-16 — — CN disclosed
WO-2016144703-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2016-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119211-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885
US-10570094-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885
US-20200115341-A1 FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885
US-11072585-B2 Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof LOXL2, LOXL1, LOX CACNA1H 4259/4885CACNA1B 3589/4885CACNA1C 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback